Close
CDMO Safety Testing 2026
Novotech

News

SBRI invests ยฃ8.7 to help develop healthcare projects

GPs and general practices are under serious pressure through increasing workloads not least due to more complex cases and the health challenges of an aging population. The ten funded companies all recognise current technology and pathway...

New prescriptions of Esyma are suspended by MHRA

In December, the EMAโ€™s Pharmacovigilance Risk Assessment Committee (PRAC) started a review of the treatment for abnormal bleeding in women with uterine fibroids after four cases of serious liver injury - three resulting in a liver transplant - were...

Richard Wolf Announces the Opening of New Office in Singapore

Richard Wolf, answering strong global demand for its high-performance endoscopic technology services, today announced plans to expand in Southeast Asia by opening its 15th subsidiary to be located at the heart of Southeast Asia โ€“ Singapore. ...

Larotrectinib data published in The New England Journal of Medicine: Bayer

Bayer and Loxo Oncology, Inc., , a biopharmaceutical company from Stamford announced the publication in The New England Journal of Medicine (NEJM) of larotrectinib data for the treatment of pediatric and adult patients whose tumors harbor Neurotrophic Tyrosine Receptor...

Envigo appoints Lynn Lewis as Senior Vice President of Global Sales

Envigo, a leading provider of nonclinical contract research services and research models, announced the appointment of Lynn Lewis to the position of Senior Vice President, Global Sales. She brings extensive knowledge in both science and business...

Bristol-Myers Squibb and Nektar Therapeutics to collaborate for Nektarโ€™s CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb Company announced the companies have executed a global strategic development and commercialization collaboration for Nektarโ€™s lead immuno-oncology program, NKTR-214. Under the collaboration, the companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers...

Saneca Pharma appoints new CEO

Contract development and manufacturing organisation (CDMO) Saneca Pharma has announced the appointment of its new CEO, Richard Krรกl. Richard, who has been the sales and marketing director at Saneca for almost three years, has previously worked...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป